Stifel lowered the firm’s price target on Cipher Pharmaceuticals (CPHRF) to C$17 from C$19 and keeps a Buy rating on the shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CPHRF:
- Cipher Pharmaceuticals Q3 2024 Results: Growth and Acquisitions
- Cipher Pharmaceuticals’ Revenue Soars After Natroba Acquisition
- CPHRF Earnings this Week: How Will it Perform?
- Cipher Pharmaceuticals Announces Q3 2024 Financial Results
- Cipher Pharmaceuticals price target raised to C$19 from C$17 at Stifel
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue